The dopamine agonist piribedil exerts hepatoprotective effects on carbon tetrachloride-induced hepatic damage

Comparative Clinical Pathology volume 22, pages413–419(2013)Cite this article

Abstract

This study aimed to investigate the effect of piribedil, a drug used for the treatment of Parkinson’s disease and which has direct dopaminergic stimulating action, on the acute hepatic injury in mice. Hepatotoxicity was induced by CCl4 orally (0.28 ml/kg). Piribedil at three dose levels (4.5, 9, or 18 mg/kg) or silymarin (25 mg/kg) was given orally daily for 7 days, starting at time of administration of CCl4. Liver damage was assessed by determining liver serum enzyme activities and by hepatic histopathology. Piribedil administration lessened the increases in serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) and also prevented the development of hepatic necrosis caused by CCl4. The effect of piribedil was dose-dependent one. Piribedil administered at the above doses caused significant reduction in the elevated plasma ALT by −36.3%, −42.8%, and −52.4% and ALP by −25%, −36.9%, and −57.1%, respectively. AST decreased by −36.4% and −46.2% by piribedil at 9 or 18 mg/kg, respectively. In comparison, the elevated serum ALT, AST, and ALP levels decreased to −69.6%, −64.2%, and −68.5% of control values, respectively, by silymarin. Histopathologic examination of the livers of CCl4-treated mice administered piribedil at 9 mg/kg showed noticeable amelioration of the liver tissue damage, while piribedil at 18 mg/kg resulted in restoration of the normal architecture of the liver tissue as well as noticeable increase in the protein content of hepatocytes. It is concluded that administration of the dopaminergic agonist piribedil in a model of liver injury induced by CCl4 results in amelioration of liver damage.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

US$ 39.95

Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2

References

  1. Bacq Y, Gaudin C, Hadengue A, Roulot D, Braillon A, Moreau R, Lebrec D (1991) Systemic, splanchnic and renal hemodynamic effects of a dopaminergic dose of dopamine in patients with cirrhosis. Hepatology 14:483–487

    PubMed  Article  CAS  Google Scholar 

  2. Baraldi M, Zeneroli ML, Ricci P, Caselgrandi E, Ventura E (1983) Down regulation of striatal dopamine receptors in experimental hepatic encephalopathy. Life Sci 32:1417–1425

    PubMed  Article  CAS  Google Scholar 

  3. Beck GCh, Brinkkoetter P, Hanusch C, Schulte J, van Ackern K, van der Woude FJ, Yard BA (2004) Clinical review: immunomodulatory effects of dopamine in general inflammation. Crit Care 8:485–491

    PubMed  Article  Google Scholar 

  4. Belfield A, Goldberg DM (1971) Revised assay for serum phenyl phosphatase activity using 4-amino-antipyrine. Enzyme 12:561–573

    PubMed  CAS  Google Scholar 

  5. Buylaert WA (1977) Femoral vasodilatation produced by piribedil (ET495) and its metabolite S584 in the hindleg of the dog. Naunyn Schmiedebergs Arch Pharmacol 299:101–103

    PubMed  Article  CAS  Google Scholar 

  6. Caldwell MA, Reymann JM, Bentue-Ferrer D, Allain H, Leonard BE (1996) The dopamine agonists lisuride and piribedil protect against behavioural and histological changes following 4-vessel occlusion in the rat. Neuropsychobiology 34:117–124

    PubMed  Article  CAS  Google Scholar 

  7. Calzi F, Bellasio R, Guiso G, Caccia S, Tacconi MT (1997) Effect of piribedil and its metabolite, S584, on brain lipid peroxidation in vitro and in vivo. Eur J Pharmacol 338:185–190

    PubMed  Article  CAS  Google Scholar 

  8. Crowley LV (1967) The Reitman–Frankel colorimetric transaminase procedure in suspected myocardial infarction. Clin Chem 13:482–487

    PubMed  CAS  Google Scholar 

  9. Delbarre B, Delbarre G, Rochat C, Calinon F (1995) Effect of piribedil, a D-2 dopaminergic agonist, on dopamine, amino acids, and free radicals in gerbil brain after cerebral ischemia. Mol Chem Neuropathol 26:43–52

    PubMed  Article  CAS  Google Scholar 

  10. Flora K, Hahn M, Rosen H, Benner K (1998) Milk thistle (Silybum marianum) for the therapy of liver disease. Am J Gastroenterol 93:139–143

    PubMed  Article  CAS  Google Scholar 

  11. Giullian JA, Marsh JW, Chung OK, Drougas JG, Wright JK, Chapman WC, Blair KT, Barnard SE, Feurer ID, Pinson CW (2000) Effect of dopamine infusion (3–30 microg/kg/min) on hepatic hemodynamics. J Surg Res 88:52–57

    PubMed  Article  CAS  Google Scholar 

  12. Goldberg LI (1972) Cardiovascular and renal actions of dopamine: potential clinical applications. Pharmacol Rev 24:1–29

    PubMed  CAS  Google Scholar 

  13. Goldberg LI (1975) The dopamine vascular receptor. Biochem Pharmacol 24:651–653

    PubMed  Article  CAS  Google Scholar 

  14. Haas DA, George SR (1988) Single or repeated mild stress increases synthesis and release of hypothalamic corticotropin releasing factor. Brain Res 461:230–237

    PubMed  Article  CAS  Google Scholar 

  15. Halpenny M, Lakshmi S, O'Donnell A, O'Callaghan-Enright S, Shorten GD (2001) Fenoldopam: renal and splanchnic effects in patients undergoing coronary artery bypass grafting. Anaesthesia 56:953–960

    PubMed  Article  CAS  Google Scholar 

  16. Hasselgren PO, Biber B, Fornander J (1983) Improved blood flow and protein synthesis in the postischemic liver following infusion of dopamine. J Surg Res 34:44–52

    PubMed  Article  CAS  Google Scholar 

  17. Hiroyuki S, Shinji U (2004) Mechanism of postoperative liver dysfunction and its management. Surgical Therapy 90:752–756

    Google Scholar 

  18. Hsu CT, Schichijo K, Ito M, Sekine I (1993) The effect of chemical sympathectomy on acute liver injury induced by carbon tetrachloride in spontaneously hypertensive rats. J Auton Nerv Syst 43:91–96

    PubMed  Article  CAS  Google Scholar 

  19. Jain CK, Vishwanathan N (2007) Parkinson’s disease: a perilous magic of nature. Scientific Research and Essays 2:251–255

    Google Scholar 

  20. Kalin N, Takahashi L, Chen F (1994) Restraint stress increases corticotropin-releasing hormone mRNA content in the amygdala and paraventricular nucleus. Brain Res 656:182–186

    PubMed  Article  CAS  Google Scholar 

  21. Kim ZG, Sanli E, Brinkmann L, Lorenz M, Gutt CN (2002) Impact of dopamine and endothelin-1 antagonism on portal venous blood flow during laparoscopic surgery. Surgical Endoscopy 16:1292–1296

    PubMed  Article  Google Scholar 

  22. Konstandi M, Harkitis P, Kostakis D, Marselos M, Johnson EO, Lang MA (2008) D2-receptor-linked signaling pathways regulate the expression of hepatic CYP2E1. Life Sci 82:1–10

    PubMed  Article  CAS  Google Scholar 

  23. Kornbrust DJ, Bus JS (1984) Glutathione depletion by methyl chloride and association with lipid peroxidation in mice and rats. Toxicol Appl Pharmacol 72:388–399

    PubMed  Article  CAS  Google Scholar 

  24. Laubie M, Schmitt H (1978) Inhibitory effects of piribedil on adrenergic neurotransmission. Eur J Pharmacol 52:99–107

    PubMed  Article  CAS  Google Scholar 

  25. Marcano H, Novoa E, Friedman E, Crespo A, Tortoledo M, Sanchez de Leon R (2001) Effect of dopamine on platelet activating factor induced-pulmonary edema in isolated and perfused rabbit lungs. Respir Physiol 126:153–162

    PubMed  Article  CAS  Google Scholar 

  26. Mazia D, Drewer PA, Alfert M (1953) The cytochemical staining and measurement of protein with mercaric bromophenol blue. Biol Bull 104:57–67

    Article  CAS  Google Scholar 

  27. McCulloch J, Edvisson L (1980) Cerebral circulatory and metabolic effects of piribedil. Eur J Pharmacol 66:327–337

    PubMed  Article  CAS  Google Scholar 

  28. Millan MJ (2010) From the cell to the clinic: a comparative review of the partial D2/D3receptor agonist and α2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson's disease. Pharmacol Ther 128:229–273

    PubMed  Article  CAS  Google Scholar 

  29. Mindham RH, Lamb P, Bradley R (1977) A comparison of piribedil, procyclidine and placebo in the control of phenothiazine-induced parkinsonism. Br J Psychiatr 130:581–585

    Article  CAS  Google Scholar 

  30. Mitchell IM, Pollock JCS, Jam MPG (1995) Effects of dopamine on liver blood flow in children with congenital heart disease. Ann Thorac Surg 60:1741–1744

    PubMed  Article  CAS  Google Scholar 

  31. Montosi G, Garuti C, Iannone A, Pietrangelo A (1998) Spatial and temporal dynamics of hepatic stellate cell activation during oxidant-stress-induced fibrogenesis. Am J Pathol 152:1319–1326

    PubMed  CAS  Google Scholar 

  32. Mousseau DD, Perney P, Layrargues GP, Butterworth RF (1993) Selective loss of pallidal dopamine D2 receptor density in hepatic encephalopathy. Neuroscience Letters 162:192–196

    PubMed  Article  CAS  Google Scholar 

  33. Muriel P, Alba N, Perez-Alvarez VM, Shibayama M, Tsutsumi VK (2001) Kupffer cells inhibition prevents hepatic lipid peroxidation and damage induced by carbon tetrachloride. Comp Biochem Physiol C Toxicol Pharmacol 130:219–226

    PubMed  Article  CAS  Google Scholar 

  34. Nagaraja DM, Jayashree S (2001) Randomized study of the dopamine receptor agonist piribedil in the treatment of mild cognitive impairment. Am J Psychiatry 158:1517–1519

    PubMed  Article  CAS  Google Scholar 

  35. Nakade Y, Yoneda M, Nakamura K, Makino I, Terano A (2002) Involvement of endogenous CRF in carbon tetrachloride-induced acute liver injury in rats. Am J Physiol Regul Integr Comp Physiol 282:R1782–R1788

    PubMed  CAS  Google Scholar 

  36. Paget GE, Barnes JM (1964) Toxicity testing. In: Laurence DR, Bacharach AL (eds) Evaluation of drug activities pharmacometrics. Academic, London, pp 1–135

    Google Scholar 

  37. Poli G (2000) Pathogenesis of liver fibrosis: role of oxidative stress. Mol Asp Med 21:49–98

    Article  CAS  Google Scholar 

  38. Rascol O, Dubois B, Caldas AC, Senn S, Del Signore S, Lees A, Parkinson REGAIN Study Group (2006) Early piribedil monotherapy of Parkinson's disease: a planned seven-month report of the REGAIN study. Mov Disord 21:2110–2115

    PubMed  Article  Google Scholar 

  39. Saller R, Meier R, Brignoli R (2001) The use of silymarin in the treatment of liver diseases. Drugs 61:2035–2063

    PubMed  Article  CAS  Google Scholar 

  40. Sato Y, Yoneda M, Nakamura K, Makino I, Terano A (2003) Protective effect of central thyrotropin-releasing hormone on carbon tetrachloride-induced acute hepatocellular necrosis in rats. J Hepatol 39:47–54

    PubMed  Article  CAS  Google Scholar 

  41. Seri I, Eklöf AC, Aperia A (1987) Role of dopamine2-receptors in mediating renal vascular response to low dose dopamine infusion in the rat. Acta Physiol Scand 130:563–569

    PubMed  Article  CAS  Google Scholar 

  42. Smith L, De Salvia M, Jenner P, Marsden CD (1966) An appraisal of the antiparkinsonian activity of piribedil in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets. Movement Disorders 11:125–135

    Article  Google Scholar 

  43. Tamori K, Yoneda M, Nakamura K, Makino I (1998) Effect of intracisternal thyrotropin-releasing hormone on hepatic blood flow in rats. Am J Physiol 274:G277–G282

    PubMed  CAS  Google Scholar 

  44. Tanaka N, Tanaka K, Nagashima Y, Kondo M, Sekihara H (1999) Nitric oxide increases hepatic arterial blood flow in rats with carbon tetrachloride-induced acute hepatic injury. Gastroenterology 117:173–180

    PubMed  Article  CAS  Google Scholar 

  45. Tomasi A, Albano E, Banni S, Botti B, Corongiu F, Dessi MA, Iannone A, Vannini V, Dianzani MU (1987) Free-radical metabolism of carbon tetrachloride in rat liver mitochondria. A study of the mechanism of activation. Biochem J 246:313–317

    PubMed  CAS  Google Scholar 

  46. Turle-Lorenzo N, Maurin B, Puma C, Chezaubernard C, Morain P, Baunez C, Nieoullon A, Amalric M (2006) The dopamine agonist piribedil with L-DOPA improves attentional dysfunction: relevance for Parkinson's disease. J Pharmacol Exp Ther 319:914–923

    PubMed  Article  CAS  Google Scholar 

  47. Uyama N, Geerts A, Reynaert H (2004) Neural connections between the hypothalamus and the liver. The Anatomical Record Part A: Discoveries in Molecular, Cellular, and Evolutionary Biology 280A:808–820

    Article  Google Scholar 

  48. Velasco M, Luchsinger A (1998) Dopamine: pharmacologic and therapeutic aspects. Am J Ther 5:37–43

    PubMed  Article  CAS  Google Scholar 

  49. Wójcikowski J, Daniel WA (2011) The role of the nervous system in the regulation of liver cytochrome p450. Curr Drug Metab 12:124–138

    PubMed  Article  Google Scholar 

  50. Yano M, Adachi N, Liu K, Arai T (2005) Flumazenil-induced improvement of the central dopaminergic system in rats with acute hepatic failure. J Neurosurg Anesthesiol 17:69–74

    PubMed  Article  Google Scholar 

  51. Yokohama S, Yoneda M, Nakamura K, Makino I (1999) Effect of central corticotropin-releasing factor on carbon tetrachloride-induced acute liver injury in rats. Am J Physiol 276:G622–G662

    PubMed  CAS  Google Scholar 

  52. Yoneda M, Tamori K, Sato Y, Yokohama S, Nakamura K, Makino I (1997) Central thyrotropin-releasing hormone stimulates hepatic DNA synthesis in rats. Hepatology 26:1203–1208

    PubMed  Article  CAS  Google Scholar 

  53. Yoneda M, Nakamura K, Nakade Y, Tamano M, Kono T, Watanobe H, Shimada T, Hiraishi H, Terano A (2005) Effect of central corticotropin releasing factor on hepatic circulation in rats: the role of the CRF2 receptor in the brain. Gut 54:282–288

    PubMed  Article  CAS  Google Scholar 

  54. Zhang S, Peng XG, Liu CC, Liu H, Lu Y (2007) Low-dose dopamine reduces inflammatory factors of acute pancreatitis in rats. Hepatobiliary Pancreat Dis Int 6:646–649

    PubMed  CAS  Google Scholar 

  55. Ziegler M, Rondot P (1999) Action of piribedil in Parkinson's disease. Multicenter study. Presse Med 28:1414–1418

    PubMed  CAS  Google Scholar 

Download references

Author information

Affiliations

  1. Department of Toxicology and Narcotics, National Research Centre, Tahrir St, Dokki, Cairo, Egypt

    Omar M. E. Abdel-Salam

  2. Department of Pharmacology, National Research Centre, Cairo, Egypt

    Amany A. Sleem

  3. Department of Pathology, National Research Centre, Cairo, Egypt

    Nermeen Shafee

Authors
  1. Omar M. E. Abdel-Salam
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amany A. Sleem
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nermeen Shafee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Omar M. E. Abdel-Salam.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Abdel-Salam, O.M.E., Sleem, A.A. & Shafee, N. The dopamine agonist piribedil exerts hepatoprotective effects on carbon tetrachloride-induced hepatic damage. Comp Clin Pathol 22, 413–419 (2013). https://doi.org/10.1007/s00580-012-1425-6

Download citation

Keywords

  • Piribedil
  • Hepatic injury
  • Mice
  • CCl4